LT3288944T - Imidazopirazinonai, kaip pde1 inhibitoriai - Google Patents

Imidazopirazinonai, kaip pde1 inhibitoriai

Info

Publication number
LT3288944T
LT3288944T LTEP16720101.1T LT16720101T LT3288944T LT 3288944 T LT3288944 T LT 3288944T LT 16720101 T LT16720101 T LT 16720101T LT 3288944 T LT3288944 T LT 3288944T
Authority
LT
Lithuania
Prior art keywords
imidazopyrazinones
pde1
inhibitors
Prior art date
Application number
LTEP16720101.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jan Kehler
Lars Rasmussen
Morten LANGGÅRD
Mikkel JESSING
Paulo Vital
Karsten Juhl
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of LT3288944T publication Critical patent/LT3288944T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP16720101.1T 2015-04-30 2016-04-29 Imidazopirazinonai, kaip pde1 inhibitoriai LT3288944T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en) 2015-04-30 2016-04-29 Imidazopyrazinones as pde1 inhibitors

Publications (1)

Publication Number Publication Date
LT3288944T true LT3288944T (lt) 2019-07-25

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16720101.1T LT3288944T (lt) 2015-04-30 2016-04-29 Imidazopirazinonai, kaip pde1 inhibitoriai

Country Status (42)

Country Link
US (4) US20160318939A1 (enExample)
EP (1) EP3288944B1 (enExample)
JP (1) JP6663930B2 (enExample)
KR (1) KR102605759B1 (enExample)
CN (1) CN107531714B (enExample)
AU (1) AU2016256573B2 (enExample)
BR (1) BR112017023182B1 (enExample)
CA (1) CA2983563A1 (enExample)
CL (1) CL2017002719A1 (enExample)
CO (1) CO2017010399A2 (enExample)
CY (1) CY1121806T1 (enExample)
DK (1) DK3288944T3 (enExample)
DO (1) DOP2017000254A (enExample)
EA (1) EA031946B1 (enExample)
EC (1) ECSP17072228A (enExample)
ES (1) ES2735422T3 (enExample)
GE (2) GEAP201914615A (enExample)
GT (1) GT201700223A (enExample)
HK (1) HK1252098B (enExample)
HR (1) HRP20191180T1 (enExample)
HU (1) HUE044244T2 (enExample)
IL (1) IL255316B (enExample)
JO (1) JO3627B1 (enExample)
LT (1) LT3288944T (enExample)
MA (1) MA41977B1 (enExample)
ME (1) ME03414B (enExample)
MX (1) MX375737B (enExample)
MY (1) MY182382A (enExample)
PE (1) PE20180121A1 (enExample)
PH (1) PH12017501990B1 (enExample)
PL (1) PL3288944T3 (enExample)
PT (1) PT3288944T (enExample)
RS (1) RS59051B1 (enExample)
RU (1) RU2712219C2 (enExample)
SG (1) SG11201708822PA (enExample)
SI (1) SI3288944T1 (enExample)
SM (1) SMT201900393T1 (enExample)
TN (1) TN2017000428A1 (enExample)
TW (1) TWI695838B (enExample)
UA (1) UA123050C2 (enExample)
WO (1) WO2016174188A1 (enExample)
ZA (1) ZA201706847B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
LT3532064T (lt) * 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20220184240A1 (en) 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
MXPA06011423A (es) * 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
AU2009322899A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005934A (es) * 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
SI3339323T1 (sl) 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
MX381326B (es) * 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
US20170066741A1 (en) 2014-02-19 2017-03-09 H. Lundbeck A/S 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
RU2018104868A (ru) 2015-08-12 2019-09-13 Х. Лундбекк А/С 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui

Also Published As

Publication number Publication date
MA41977B1 (fr) 2019-08-30
ME03414B (me) 2020-01-20
CA2983563A1 (en) 2016-11-03
RU2017137514A3 (enExample) 2019-07-17
JO3627B1 (ar) 2020-08-27
MY182382A (en) 2021-01-22
EP3288944A1 (en) 2018-03-07
US20170291903A1 (en) 2017-10-12
KR20170140216A (ko) 2017-12-20
IL255316B (en) 2021-10-31
KR102605759B1 (ko) 2023-11-23
AU2016256573A1 (en) 2017-12-14
HK1252098B (en) 2020-02-07
CN107531714B (zh) 2019-07-19
PT3288944T (pt) 2019-07-19
BR112017023182A2 (enExample) 2018-10-02
EP3288944B1 (en) 2019-06-12
US10011606B2 (en) 2018-07-03
ECSP17072228A (es) 2018-02-28
SG11201708822PA (en) 2017-11-29
ES2735422T3 (es) 2019-12-18
JP6663930B2 (ja) 2020-03-13
IL255316A0 (en) 2017-12-31
US10858362B2 (en) 2020-12-08
EA031946B1 (ru) 2019-03-29
GEP20207058B (en) 2020-01-27
PH12017501990B1 (en) 2021-01-13
EA201792157A1 (ru) 2018-03-30
JP2018514552A (ja) 2018-06-07
MX2017013785A (es) 2018-03-27
SMT201900393T1 (it) 2019-09-09
GT201700223A (es) 2018-12-19
RU2712219C2 (ru) 2020-01-27
MA41977A (fr) 2018-07-23
GEAP201914615A (en) 2019-09-25
HRP20191180T1 (hr) 2019-10-04
TWI695838B (zh) 2020-06-11
WO2016174188A1 (en) 2016-11-03
DK3288944T3 (da) 2019-07-22
BR112017023182B1 (pt) 2023-10-31
CN107531714A (zh) 2018-01-02
CY1121806T1 (el) 2020-07-31
PH12017501990A1 (en) 2018-03-26
ZA201706847B (en) 2019-01-30
TW201700477A (zh) 2017-01-01
PL3288944T3 (pl) 2019-11-29
MX375737B (es) 2025-03-06
PE20180121A1 (es) 2018-01-18
TN2017000428A1 (en) 2019-04-12
RS59051B1 (sr) 2019-08-30
HUE044244T2 (hu) 2019-10-28
HK1252098A1 (en) 2019-05-17
US20210238182A1 (en) 2021-08-05
US11472810B2 (en) 2022-10-18
UA123050C2 (uk) 2021-02-10
US20160318939A1 (en) 2016-11-03
US20190062335A1 (en) 2019-02-28
AU2016256573B2 (en) 2019-11-21
CO2017010399A2 (es) 2018-01-05
CL2017002719A1 (es) 2018-04-20
SI3288944T1 (sl) 2019-08-30
DOP2017000254A (es) 2018-01-15
RU2017137514A (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3377059A4 (en) INHIBITORS OF CXCR2
DK3072835T3 (da) Fremgangsmåde til fremføring
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
MA44474A (fr) Nouveaux inhibiteurs de la ferroportine
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
MA44006A (fr) Inhibiteur pde1
EP3386505A4 (en) AZA-BENZIMIDAZOLINHIBITORS OF PAD4
DK3341379T3 (da) EZH2-hæmmere
PL3258674T3 (pl) Wybór procedury ukrywania straty pakietu
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3283210T3 (da) Fremgangsmåde
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3331498T3 (da) Nasalsammensætning
EP3328991A4 (en) BIOSYNTHESIS OF POLYCETIDES
HUE046994T2 (hu) Pirido-oxazinon származékok TNAP inhibitorokként
IL254502B (en) Solid forms of menaquinols
LT3126354T (lt) Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai
CL2016001959A1 (es) Hexahidrofuropirroles como inhibidores de pde1
EP3286306A4 (en) NEW PROCESS